STOCK TITAN
  1. Home
  2. Sec-filings
  3. BBNX
  4. [Form 4] Beta Bionics, Inc. Insider Trading Activity

Beta Bionics (BBNX) director receives 16,965-share equity award

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Palasis Maria reported acquisition or exercise transactions in this Form 4 filing.

Beta Bionics, Inc. director Maria Palasis received an equity award of 16,965 shares of Common Stock on May 21, 2026. The grant was issued at no cash cost as a restricted stock unit award under the company’s 2025 Equity Incentive Plan, bringing her direct holdings to 29,397 shares.

Positive

  • None.

Negative

  • None.
Insider Palasis Maria
Role null
Type Security Shares Price Value
Grant/Award Common Stock 16,965 $0.00 --
Holdings After Transaction: Common Stock — 29,397 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Equity award size 16,965 shares Restricted stock unit award on May 21, 2026
Shares after transaction 29,397 shares Direct Common Stock holdings following the grant
Reported grant price $0.0000 per share Form 4 transaction price for the awarded shares
Transaction code A (Grant, award, or other acquisition) Non-derivative Common Stock acquisition classification
restricted stock unit award financial
"Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan."
A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.
2025 Equity Incentive Plan financial
"Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan."
Common Stock financial
"security_title: "Common Stock" in the reported non-derivative transaction."
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition" for the Form 4 entry."
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Palasis Maria
(Last)(First)(Middle)
C/O BETA BIONICS, INC.
11 HUGHES
(Street)
IRVINE CALIFORNIA 92618
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/21/2026A16,965(1)A$029,397D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.
/s/ Stephen Feider, Attorney-in-Fact05/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Beta Bionics (BBNX) report for Maria Palasis?

Beta Bionics reported that director Maria Palasis received an equity award of 16,965 shares of Common Stock. The award was granted as restricted stock units under the company’s 2025 Equity Incentive Plan, increasing her direct holdings to 29,397 shares.

Was the Beta Bionics (BBNX) insider award an open-market purchase or a grant?

The transaction was a grant, not an open-market purchase. Maria Palasis received 16,965 shares as a restricted stock unit award under the 2025 Equity Incentive Plan, with a recorded price of $0.0000 per share in the filing’s transaction details.

How many Beta Bionics (BBNX) shares does Maria Palasis hold after this Form 4?

After the reported transaction, Maria Palasis directly holds 29,397 shares of Beta Bionics Common Stock. This reflects the addition of 16,965 shares from the restricted stock unit award granted under the company’s 2025 Equity Incentive Plan on May 21, 2026.

What plan governed the 16,965-share award to the Beta Bionics (BBNX) director?

The 16,965-share award to director Maria Palasis was granted under Beta Bionics’ 2025 Equity Incentive Plan. The filing’s footnote clarifies that the transaction represents a restricted stock unit award issued pursuant to this equity compensation program for company insiders.

Does the Beta Bionics (BBNX) Form 4 show any insider share sales?

No insider share sales are reported in this Form 4. The filing shows a single acquisition transaction classified as a grant or award, where director Maria Palasis received 16,965 shares, increasing her total direct holdings to 29,397 shares of Common Stock.